Business Wire

NY-SULLIVAN-&-CROMWELL

3.1.2022 15:48:09 CET | Business Wire | Press release

Share
Robert J. Giuffra, Jr. and Scott Miller Become Co-Chairs of Sullivan & Cromwell LLP

Sullivan & Cromwell LLP announced today that Robert J. Giuffra, Jr. and Scott Miller have become Co-Chairs of the firm, effective January 1, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005204/en/

Mr. Giuffra and Mr. Miller have served as Vice Chairs of the firm since January 2021. They succeed Joseph C. Shenker, the firm’s Chair since 2010, who will continue to serve on the firm’s Management Committee as Senior Chair in addition to continuing with his active client practice.

“Since the days of our founders, Sullivan & Cromwell has an unwavering commitment to our clients, our people and our communities,” said Mr. Shenker. “Bob and Scott exemplify these qualities, long ago establishing themselves as trusted counselors whose complementary strengths in litigation and corporate law reflect the broad scope of work we do for our clients around the world.”

“Our firm’s international practice and ability to deliver integrated client service through our network of 13 offices across four continents are critical to our success,” said Mr. Miller. “More than half of our firm’s clients are headquartered outside the United States, and Bob and I have each spent our careers handling our clients’ most complex cross-border matters. As the world becomes even more integrated and the issues clients face become more complex, we expect our global practice to be a driver of our firm’s continued success.”

“I am honored to work with Scott and our partners to build on our firm’s strong culture of excellence, innovation and commitment to our clients and each other,” said Mr. Giuffra. “For 143 years, our model has been tried and true: to recruit and train the best lawyers to work together to help our clients solve their most critical challenges and capture their highest value opportunities.”

Mr. Giuffra, a nationally prominent litigator, joined S&C in 1989 after serving as a law clerk to Chief Justice William Rehnquist of the U.S. Supreme Court and Judge Ralph Winter of the U.S. Court of Appeals for the Second Circuit. Based in New York, he has been a member of Sullivan & Cromwell’s Management Committee since 2007. A fellow of the American College of Trial Lawyers and International Academy of Trial Lawyers, he has successfully represented the firm’s clients in multi-billion dollar trials, litigations and government investigations. He has played a significant role in navigating some of the biggest corporate crises of the past 20 years, including the bankruptcy of Enron, the accounting frauds at Computer Associates and HealthSouth Corporation, the financial crisis, and the Volkswagen diesel emissions crisis for which he served as the carmaker’s national coordinating counsel. His current clients include Allianz, Goldman Sachs, Stellantis, UBS and Volkswagen. He has represented corporate boards and directors, CEOs, senior public officials, prominent families, law firms and professional sports teams.

Mr. Miller, a premier corporate counselor, joined S&C in 1986 after serving as a law clerk to Judge William A. Norris of the U.S. Court of Appeals for the Ninth Circuit. He routinely handles multi-billion dollar M&A, capital markets and other strategic transactions, internal and government investigations and other corporate crises. Now based in New York, he has been a member of the Firm’s Management Committee since 2014 and coordinates our U.S. and European corporate practices. He has worked on M&A and securities transactions in more than 20 countries, including the first privatization in Italy and the first German LBO. He represented Fiat Chrysler in its $60 billion merger with Peugeot, which transformed the global auto industry through the creation of Stellantis. Earlier, he represented Fiat in connection with its 2009 rescue of Chrysler, Ferrari in its 2015 IPO, and Alcan in fighting off a hostile takeover offer from Alcoa and in its $46 billion acquisition by Rio Tinto. He has represented DISH Network for two decades and recently in a series of transactions that helped it form and fund its nationwide wireless communications network. He has also recently been in the forefront of the SPAC market, representing among others DraftKings in its de-SPAC listing and other acquisitions and financings to create one of the world’s largest digital sports entertainment and gaming companies and Ermenegildo Zegna Group in its merger with a SPAC sponsored by Investindustrial through which Zegna became a NYSE-listed company, with an initial market capitalization in excess of $3 billion.

Mr. Giuffra is a graduate of Princeton University and Yale Law School. He has served as Chief Counsel of the U.S. Senate Banking Committee and as President of the Federal Bar Council. He is a member of New York’s Permanent Commission on Access to Justice and the Standing Committee on Rules of Practice and Procedure of the U.S. Courts. He is chair of the American Swiss Foundation.

Mr. Miller is a graduate of Arizona State University and Columbia Law School. He was managing partner of Sullivan & Cromwell’s Palo Alto office and has been resident in the firm’s London and Los Angeles offices. He is a trustee of the United States Council for International Business.

About Sullivan & Cromwell LLP

Sullivan & Cromwell LLP is a global law firm that advises on significant litigation, corporate investigations and complex regulatory, major domestic and cross-border M&A, finance, corporate and restructuring transactions, tax and estate planning matters. Founded in 1879, Sullivan & Cromwell has approximately 900 lawyers located in offices in New York, Washington, Los Angeles, Palo Alto, London, Frankfurt, Paris, Brussels, Hong Kong, Beijing, Tokyo, Melbourne and Sydney.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye